Eledon Pharmaceuticals (ELDN) reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-transplant.
The subjects were treated with an immunosuppression regimen that includes tegoprubart, Eledon's investigational anti-CD40L antibody, aimed at preventing islet transplant rejection in individuals with type 1 diabetes.
The trial showed the potential first human cases of the achievement of insulin independence using an anti-CD40L monoclonal antibody therapy without tacrolimus, the current standard of care to prevent transplant rejection, the company said Tuesday in a statement.
The third subject lowered insulin use by 60% three days after receiving an islet transplant and remains on track for insulin independence, the company said.
The company said treatment with tegoprubart was generally well-tolerated.
Eledon shares rose 11% in recent Tuesday trading.
Price: 3.75, Change: +0.38, Percent Change: +11.28
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。